Compare Lupin Ltd with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs STRIDES PHARMA SCIENCE - Comparison Results

LUPIN     Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN STRIDES PHARMA SCIENCE LUPIN/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 47.5 14.5 326.2% View Chart
P/BV x 2.4 0.9 283.0% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 LUPIN   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    LUPIN
Mar-19
STRIDES PHARMA SCIENCE
Mar-18
LUPIN/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs9861,147 86.0%   
Low Rs720642 112.2%   
Sales per share (Unadj.) Rs369.5317.2 116.5%  
Earnings per share (Unadj.) Rs13.47.8 170.9%  
Cash flow per share (Unadj.) Rs37.425.1 149.2%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs303.7274.3 110.7%  
Shares outstanding (eoy) m452.4989.50 505.6%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.32.8 81.9%   
Avg P/E ratio x63.6114.0 55.8%  
P/CF ratio (eoy) x22.835.7 63.9%  
Price / Book Value ratio x2.83.3 86.1%  
Dividend payout %025.5 0.0%   
Avg Mkt Cap Rs m386,06480,058 482.2%   
No. of employees `00017.72.5 705.4%   
Total wages/salary Rs m31,5134,341 726.0%   
Avg. sales/employee Rs Th9,453.811,325.8 83.5%   
Avg. wages/employee Rs Th1,782.01,731.4 102.9%   
Avg. net profit/employee Rs Th343.0280.1 122.5%   
INCOME DATA
Net Sales Rs m167,18228,394 588.8%  
Other income Rs m3,640941 387.0%   
Total revenues Rs m170,82229,334 582.3%   
Gross profit Rs m28,8223,965 726.8%  
Depreciation Rs m10,8501,540 704.4%   
Interest Rs m3,0781,962 156.9%   
Profit before tax Rs m18,5341,403 1,320.8%   
Minority Interest Rs m-890-   
Prior Period Items Rs m38-168 -22.3%   
Extraordinary Inc (Exp) Rs m-3,400-436 780.1%   
Tax Rs m9,01797 9,267.1%   
Profit after tax Rs m6,066702 863.9%  
Gross profit margin %17.214.0 123.4%  
Effective tax rate %48.76.9 701.6%   
Net profit margin %3.62.5 146.7%  
BALANCE SHEET DATA
Current assets Rs m138,53624,836 557.8%   
Current liabilities Rs m61,29918,993 322.7%   
Net working cap to sales %46.220.6 224.5%  
Current ratio x2.31.3 172.8%  
Inventory Days Days8471 118.0%  
Debtors Days Days112113 99.1%  
Net fixed assets Rs m127,51634,289 371.9%   
Share capital Rs m905895 101.1%   
"Free" reserves Rs m136,51723,651 577.2%   
Net worth Rs m137,42224,546 559.9%   
Long term debt Rs m66,41715,513 428.1%   
Total assets Rs m279,49465,437 427.1%  
Interest coverage x7.01.7 409.4%   
Debt to equity ratio x0.50.6 76.5%  
Sales to assets ratio x0.60.4 137.9%   
Return on assets %3.34.1 80.3%  
Return on equity %4.42.9 154.3%  
Return on capital %8.96.9 129.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m59,41415,697 378.5%   
Fx outflow Rs m22,282735 3,029.9%   
Net fx Rs m37,13214,962 248.2%   
CASH FLOW
From Operations Rs m16,6601,871 890.6%  
From Investments Rs m-32,8255,826 -563.4%  
From Financial Activity Rs m7,441-10,157 -73.3%  
Net Cashflow Rs m-8,724-2,615 333.6%  

Share Holding

Indian Promoters % 46.6 27.7 168.2%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 37.8 29.9%  
FIIs % 31.9 8.6 370.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 25.9 39.0%  
Shareholders   98,259 56,241 174.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN With:   FDC LTD.  FULFORD INDIA  DR. REDDYS LAB  AJANTA PHARMA  UNICHEM LAB  

Compare LUPIN With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

LUPIN 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (4QFY19); Net Profit Down 1.5% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, LUPIN has posted a net profit of Rs 3 bn (down 1.5% YoY). Sales on the other hand came in at Rs 44 bn (up 77.8% YoY). Read on for a complete analysis of LUPIN's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


Oct 18, 2019 (Close)

TRACK LUPIN

COMPARE LUPIN WITH

MARKET STATS